scispace - formally typeset
Q

Qingcheng Song

Researcher at Hebei Medical University

Publications -  14
Citations -  55

Qingcheng Song is an academic researcher from Hebei Medical University. The author has contributed to research in topics: Medicine & Biology. The author has an hindex of 1, co-authored 7 publications receiving 1 citations.

Papers
More filters
Journal ArticleDOI

Amplification of oxidative stress with lycorine and gold-based nanocomposites for synergistic cascade cancer therapy.

TL;DR: Huazhong University of Science and Technology https://orcid.org/0000-0002-0471-5594 Wenbo Yang Wuhan Union Hospital Zihui Liang Hubei University Zezhu Zhou HubeI University Qingcheng Song Hebei Medical University Third A liated Hospital Weijian Liu WuhAN Union Hospital
Journal ArticleDOI

Prognostic Value of the Preoperative Lymphocyte-to-C-Reactive Protein Ratio and Albumin-to-Globulin Ratio in Patients with Osteosarcoma

TL;DR: New evidence is provided that the preoperative LCR and AGR could serve as independent prognostic factors for patients with osteosarcoma and these findings will help physicians to stratify patients for appropriate treatment protocols and facilitate decision-making so as to improve the patients’ survival condition.
Journal ArticleDOI

Tumour microenvironment-responsive nanoplatform based on biodegradable liposome-coated hollow MnO2 for synergistically enhanced chemotherapy and photodynamic therapy.

TL;DR: In this paper, hollow manganese dioxide nanoparticles (HMDNs) loaded with the hydrophilic chemotherapeutic drug (acriflavine, ACF) were further encapsulated by pH-sensitive liposome to form core-shell nanocomposite, with surface modified with arginine-glycine-aspartic acid (RGD) peptide to achieve tumour targeting.
Journal ArticleDOI

Mitochondria-targeted accumulation of oxygen-irrelevant free radicals for enhanced synergistic low-temperature photothermal and thermodynamic therapy.

TL;DR: In this paper, a core-shell nanoplatform with an appropriate size composed of arginine-glycine-aspartate (RGD) functioned polydopamine (PDA) as a shell and a triphenylphosphonium (TPP) modified hollow mesoporous manganese dioxide (H-mMnO2) was designed and fabricated for the first time.